MAIA Biotechnology has dosed its first US patient in the Phase 2 THIO-101 trial expansion evaluating ateganosine for third-line non-small cell lung cancer. The milestone follows FDA clearance of an amended investigational new drug submission highlighting improved manufacturing capabilities.

The US expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation. MAIA has activated three sites in the US for this phase of the study.

Clinical Pipeline Update

MAIA holds FDA Fast Track designation for ateganosine, a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. Prior data from THIO-101 Parts A and B show overall survival beyond 24 months in eight patients receiving ateganosine sequenced with a checkpoint inhibitor.

This development complements recent positive initial efficacy data from the ongoing Phase 2 THIO-101 clinical trial expansion, Part C. In third-line studies, the treatment showed a disease control rate of 90.5% in the efficacy evaluable population who had at least one tumor scan after starting treatment.

The company is also conducting the pivotal Phase 3 trial THIO-104, which evaluates ateganosine sequenced with checkpoint inhibitor cemiplimab versus investigator’s choice in third-line non-small cell lung cancer. Statistical assessments suggest a high probability of technical success for ateganosine.

Management Commentary

Vlad Vitoc, Founder and Chief Executive Officer of MAIA, stated that dosing the first patient in the United States represents a major milestone for the ongoing Phase 2 clinical trial. He noted that collaborations with top institutions and oncologists strengthen the trial as the company evaluates ateganosine for patients in advanced stages of the disease.

Vitoc added that the data generated through the THIO-101 program may support a potential pathway toward FDA accelerated approval. With patients now enrolled across four continents, he described the study as a truly global effort focused on addressing a critical unmet need in cancer care.

Insider Transactions

Board member Ramiro Guerrero acquired 185,078 shares of MAIA common stock between August 20, 2026, and September 10, 2026. The purchases were made on the open market at an average price of $1.36 per share, totaling approximately $252,284.

Founder and CEO Vlad Vitoc purchased 73,000 shares on September 14, 2026, at an average price of $1.37 per share.

As of September 14, 2026, MAIA’s directors and officers collectively hold a 21.34% stake in the company.

MAIA Biotechnology has filed a $150 million mixed shelf offering with the US Securities and Exchange Commission. The filing allows the company to register securities for future issuance.

The submission includes Form 3 documents, which typically disclose initial beneficial ownership of securities by directors, officers, and other insiders. This regulatory step is standard for companies preparing to raise capital through public markets.

Filing Details

The SEC filing confirms the company's intent to access capital markets. Mixed shelf offerings provide flexibility, allowing issuers to offer various types of securities, such as common stock, preferred stock, or debt instruments, under a single registration statement.

No specific timeline for the sale of securities or intended use of proceeds was detailed in the provided data.